LOXL2 and neoplasm: Therefore, the complex tumor-stromal interaction of LOXL2 in PDAC tumorigenesis requires further investigation and re-evaluation of the efficacy of using anti-LOXL2 antibodies or small molecule LOXL2 inhibitors in the treatment landscape of metastatic PDAC [185].